LeoPatrizi/E+ via Getty Images Apogee Therapeutics: Analyzing the Recent Decline Amidst Innovations Apogee Therapeutics, Inc. (NASDAQ:APGE) stock has taken a breather since my last check in March. APG777, their Phase 1 SQ monoclonal antibody targeting IL- 13, was the primary focus at the time. The biologic's Phase 1 data showed that it could be dosed as infrequently as every three to six months. This would be a significant improvement over Sanofi's (SNY) multibillion-dollar Dupixent monthly dosing. I recomm ...

SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Lisa Bollinger, MD, has been appointed to the company's board of directors. Dr. Bollinger most recently served as Vice President, Regulatory Affairs, Global Regulatory ...

SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma and other inflammatory and immunology indications, today announced that members of management will participate at the following upcoming investor conferences: Jefferies Global Healthcare Conference Date: Thursday, June 6, 2024 Time: 8:30 a.m. ET Goldman Sachs 45th Annual Globa ...

Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week proof-of-concept data from Part A of the Phase 2 trial expected in 2H 2025 Pipeline-in-a-product potential with a Phase 2 in asthma expected to initiate in 2025 and plans for additional indication expansion SAN FRANCISCO and WALTHAM, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a ...

Companies have generally managed to perform well against the consensus of earnings forecasts, with around 77% of S&P 500 firms reporting in Q1 considered earnings outperformers. That rate is higher than the normal rate of around 74% recorded in the first three months of a year, with earnings outperformers beating historical trends. The main theme of this quarter’s earnings reports has been artificial intelligence, with companies reporting soaring spending on the technology. Not surprisingly, AI-based and ad ...

SAN FRANCISCO, Calif. and WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology indications (Apogee or the Company), today announced the closing of its previously announced upsized public offering of 7,790,321 shares of common stock, including the full exercise of th ...

SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology indications (Apogee or the Company), today announced the pricing of its upsized previously announced underwritten public offering of 6,774,193 shares of common stock at a public offering price pe ...

Sviatlana Lazarenka/iStock via Getty Images Apogee Therapeutics, Inc. (NASDAQ:APGE) has reported positive results from its phase 1 study using its lead candidate APG777 for the treatment of patients with moderate-to-severe Atopic Dermatitis [AD] and other inflammatory disorders. The last time I went over this biotech, it had not yet reported this data. At the time, I believed that it could create a competitive edge over other IL-13 biologics based on half-life improvement. That is, how long drug exposure in ...

Aamulya Apogee Therapeutics: Setting New Benchmarks in Atopic Dermatitis Apogee Therapeutics, Inc. (NASDAQ:APGE) reported Q4 earnings and provided pipeline updates today, inspiring a 30%-plus rally in its stock, breaching all-time highs. The company concentrates on developing biologics for conditions such as COPD and atopic dermatitis [AD]: "designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize ha ...

财务业绩 - Apogee Therapeutics, Inc.（NASDAQ:APGE）发布了2023年第四季度和全年财务业绩，现金、现金等价物和可市场证券总额为395.5百万美元[3] - 其他收入（费用），净额中，利息收入为9,018美元[12] - 其他融资费用净额为(9,150)美元[12] - 净亏损为83,985美元[12] APG777临床试验 - APG777 Phase 1健康志愿者临床试验的中期结果表明，半衰期约为75天，支持了更高曝光量的潜力，有望在诱导阶段实现比当前生物制剂疗法更好的临床反应，并有可能每3个或6个月进行维持剂量[1] - APG777的中期结果显示了潜在的最佳PK特性，包括约75天的半衰期，支持了在诱导阶段测试更高的药物暴露量以潜在实现改善的临床反应[2] 联系信息 - 投资者联系人为Noel Kurdi，联系邮箱为Noel.kurdi@apogeetherapeutics.com[12] - 媒体联系人为Dan Budwick，联系邮箱为dan@1abmedia.com[12]